Gan & Lee Pharmaceuticals. (ASX: 603087) has announced a draft proposal for a 2026 restricted stock incentive plan.
The plan proposes to grant a total of 630,000 restricted shares to the incentive recipients, representing approximately 0.1055% of the company's total share capital of 597 million shares as of the announcement date of the draft plan.
The grant price for the restricted shares is set at 27.8 yuan per share.
The incentive recipients comprise 20 individuals, including senior management and key technical or business personnel employed by the company and its subsidiaries at the time of the plan's announcement.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments